News

/News/

Strategic Partnership with Mylan NV Announced Today

Today, Atomo Diagnostics was announced as a strategic partner to Mylan N.V. as part of the global pharmaceutical company's plans to commercialize CE-Marked in vitro HIV rapid diagnostic tests for self-testing in low- and [...]

September 24th, 2018|

PRESS RELEASE: Mylan Extends Commitment to Fight HIV/AIDS by Partnering with Atomo Diagnostics to Expand Access to HIV Self-Testing in Low- and Middle-Income Countries

HERTFORDSHIRE, England, PITTSBURGH and SYDNEY, September 24, 2018 – Global pharmaceutical company Mylan N.V.(NASDAQ: MYL) and medical device company Atomo Diagnostics today announced a strategic partnership to commercialize CE-Marked in vitro [...]

September 24th, 2018|

OEM Feature: NG Biotech Case Study

From its impressive and newly expanded manufacturing plant close to the beautiful village of Guipry in northwest France, NG Biotech is rapidly scaling-up production to meet growing demand for its [...]

September 3rd, 2018|

Strategic Partnership Announcement: Atomo Diagnostics and Owen Mumford

Today, Atomo Diagnostics and Owen Mumford Ltd announced a strategic partnership for commercialisation of innovative HIV rapid tests in European markets Owen Mumford is a major healthcare company and device [...]

June 5th, 2018|

Atomo Diagnostics and Owen Mumford partner to introduce best-in-class HIV rapid testing in European markets

Sydney, Australia and Woodstock, England – 05 June 2018 | Atomo Diagnostics and Owen Mumford Ltd have today announced a strategic partnership for commercialisation of innovative HIV rapid tests in [...]

June 5th, 2018|

Joint Press Announcement: RPS Diagnostics partners with Atomo Diagnostics

RPS Diagnostics partners with Atomo Diagnostics to develop next generation FebriDx blood tests for antibiotic stewardship in the outpatient setting Sarasota, Florida and Sydney, Australia (February 20, 2018) – United [...]

February 20th, 2018|

New partnership anticipated to transform the diagnosis of febrile ARIs at the point-of-care

Atomo Diagnostics is delighted to announce it's commercial and development partnership with US biotechnology company, RPS Diagnostics. In a joint Press Announcement, the companies have shared plans to create next generation FebriDx® [...]

February 20th, 2018|

Strategic Partnership Announcement: Atomo Diagnostics and Access Bio

Today, Atomo Diagnostics and Access Bio Inc. jointly announced a strategic partnership to leverage the respective strengths of both companies and expand point of care HIV testing in global markets. [...]

January 23rd, 2018|

Atomo Diagnostics and Access Bio partner to expand access to best-in-class HIV rapid testing in global markets

Sydney, Australia and Seoul, South Korea – 23 January 2018 | Atomo Diagnostics and Access Bio Inc. today announce a strategic partnership to leverage the respective strengths of both innovative [...]

January 23rd, 2018|

Atomo HIV Self Test approved by Expert Review Panel

Atomo Diagnostics' CEO, John Kelly, today announced that the Atomo HIV Self Test has been approved by the World Health Organisation’s Expert Review Panel for Diagnostics (ERP-D); a special process determined [...]

December 6th, 2017|